Search Videos and More
News
Advancing New Treatments for Uncommon Cancer Subtypes
The biology of rare cancers is poorly understood in part because the tumors are uncommon, which makes them challenging to study. Clinical trials examining rare cancers are difficult.
News
Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch
An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows.
News
Antibody-Drug Conjugates: A Cancer Therapy Revolution
Dana-Farber researchers explore how a novel therapy may benefit patients
Symposium
Breast Cancer Treatment Guidelines
Following the FDA approval of certain treatments for breast cancer, the faculty in the Breast Oncology Program at Dana-Farber Brigham Cancer Center met to formalize guidelines for how to best utilize the new medications.
News
Breast Cancer Trial Aims to Improve Treatment for Men
Over the past 30 years, outcomes have improved dramatically for women with breast cancer. There are many new treatments, including hormone therapies and CDK4/6 inhibitors. In contrast, there has been no improvement in the outcomes for men with breast cancer. And current guidelines don’t support the use of newer therapies in men. Male breast cancer accounts for just 1% of all cases of breast cancer. Advancing care for a rare group requires a focused effort, so Jose Pablo Leone, MD, has invested energy into designing and leading a clinical trial for men with breast cancer.
Document
Breast Oncology Research Presentations Schedule
The 45th annual San Antonio Breast Cancer Symposium. December 6 - 10, 2022
News
Dana-Farber Brigham Cancer Center Launches New Program for Women with Earliest Form of Breast Cancer
Dana-Farber Brigham Cancer Center is launching a new program designed to address the unique needs of women diagnosed with the earliest form of breast cancer. Nearly 60,000 women in the United States this year will be diagnosed with Ductal carcinoma in situ (DCIS), a type of breast cancer in which cancerous cells grow but are confined within the milk duct of the breast. The new program will offer DCIS patients outstanding clinical care delivered by Dana-Farber Brigham Cancer Center experts and will be the only such program in Greater Boston offering patients access to clinical trials specific to DCIS.
News
Dana-Farber Research Supports FDA Approval of New Therapy for Metastatic Breast Cancer
Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic HR+, HER2- breast cancer.
News
Dana-Farber’s Judy Garber Is Recipient Of Brinker Award For Scientific Distinction
This year’s Brinker Award for Scientific Distinction in Clinical Research is being presented today to Judy Garber, M.D., M.P.H., Chief of the Division of Cancer Genetics and Prevention at Dana Farber Cancer Institute.
News
Dosing Strategies Help Personalize Care in HER2+ Breast Cancer
Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.
News
Final Overall Study Analysis Continues to Show Benefit of Sacituzumab Govitecan in Advanced HR+ Breast Cancer
A novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.
News
First Mammography Screening Guidelines Issued for Older Survivors of Breast Cancer
A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on the pros and cons of screening in survivors’ later years.